• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

1:1 比例 vWF/FVIII 浓缩物治疗血管性血友病患者的疗效。

Efficacy of a 1:1 ratio VWF/FVIII concentrate in patients with von Willebrand disease.

机构信息

Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

出版信息

Haemophilia. 2024 Sep;30(5):1148-1154. doi: 10.1111/hae.15079. Epub 2024 Jul 15.

DOI:10.1111/hae.15079
PMID:39010315
Abstract

INTRODUCTION

Patients with von Willebrand disease (VWD) require administration of von Willebrand factor (VWF) concentrates peri-operatively. Concerns about FVIII accumulation after repetitive injections of a 1:1 ratio VWF/FVIII clotting factor concentrate (CFC) led this study to explore the recovery and FVIII accumulation over time.

METHODS

This monocentre study examined patients with VWD receiving perioperative 1:1 ratio CFC infusions. CFC dosing was based on body weight and endogenous VWF/FVIII activity. FVIII and VWF activity was monitored at T0 (baseline), T1 (15 min postinfusion), and trough levels at T2-T6 (24-120 h).

RESULTS

We included 125 patients, undergoing 125 procedures (63 major surgeries, 62 minor), with a median of two CFC infusions (IQR 1-3). With a mean administered dose of 35.7 IU/kg CFC, recovery rates of FVIII and VWF were 2.6 IU/dL per IU/kg and 2.4 IU/dL per IU/kg, respectively. Mean FVIII levels at T0 were 62 (SD 51.9), T1: 164 (SD 80.4), T2: 155 (SD 62.8), T3: 162 (SD 59.8), T4: 124 (SD 78.4), and T5: 120 (SD 65.3) IU/dL. Mean VWF activity levels at T0 were 29 (SD 25.0), T1: 133 (SD 43.7), T2: 92 (SD 37.2), and T3: 86 (SD 37.5) IU/dL. Subgroup analysis in 47 patients with more than three infusions, showed no accumulation of mean FVIII levels.

CONCLUSION

This perioperative study demonstrated excellent FVIII and VWF recovery of a 1:1 ratio VWF product in patients with VWD. Stable FVIII and VWF activity levels were observed after repeated infusions, without accumulation. Most major surgeries required only three CFC infusions.

摘要

简介

患有血管性血友病(VWD)的患者在围手术期需要输注血管性血友病因子(VWF)浓缩物。由于担心重复输注 1:1 比例的 VWF/FVIII 凝血因子浓缩物(CFC)后会导致 FVIII 积聚,因此开展了这项研究,以探讨 VWD 患者的 VWF 恢复和 FVIII 随时间的积累情况。

方法

本单中心研究纳入了接受围手术期 1:1 比例 CFC 输注的 VWD 患者。CFC 的剂量基于体重和内源性 VWF/FVIII 活性。在 T0(基线)、T1(输注后 15 分钟)和 T2-T6(24-120 小时)时的谷底水平监测 FVIII 和 VWF 活性。

结果

我们纳入了 125 例患者,共进行了 125 次手术(63 例大手术,62 例小手术),中位输注次数为 2 次(IQR 1-3)。在平均给予 35.7 IU/kg CFC 的剂量后,FVIII 和 VWF 的恢复率分别为每 IU/kg 2.6 IU/dL 和 2.4 IU/dL。T0 时的平均 FVIII 水平为 62(SD 51.9)IU/dL,T1:164(SD 80.4)IU/dL,T2:155(SD 62.8)IU/dL,T3:162(SD 59.8)IU/dL,T4:124(SD 78.4)IU/dL,T5:120(SD 65.3)IU/dL。T0 时的平均 VWF 活性水平为 29(SD 25.0)IU/dL,T1:133(SD 43.7)IU/dL,T2:92(SD 37.2)IU/dL,T3:86(SD 37.5)IU/dL。在 47 例输注次数超过 3 次的患者中进行的亚组分析显示,FVIII 水平无蓄积。

结论

本围手术期研究表明,在 VWD 患者中,1:1 比例的 VWF 产品具有良好的 FVIII 和 VWF 恢复效果。在重复输注后,FVIII 和 VWF 活性水平稳定,无蓄积。大多数大手术只需输注 3 次 CFC。

相似文献

1
Efficacy of a 1:1 ratio VWF/FVIII concentrate in patients with von Willebrand disease.1:1 比例 vWF/FVIII 浓缩物治疗血管性血友病患者的疗效。
Haemophilia. 2024 Sep;30(5):1148-1154. doi: 10.1111/hae.15079. Epub 2024 Jul 15.
2
Analysis of current perioperative management with Haemate P/Humate P in von Willebrand disease: Identifying the need for personalized treatment.分析 von Willebrand 病围手术期应用 Haemate P/Humate P 的现状:确定个性化治疗的必要性。
Haemophilia. 2018 May;24(3):460-470. doi: 10.1111/hae.13451. Epub 2018 Mar 24.
3
Effectiveness and safety of hFVIII/VWF concentrate (Voncento) in patients with inherited von Willebrand disease requiring surgical procedures: the OPALE multicentre observational study.接受手术治疗的遗传性血管性血友病患者使用 hFVIII/VWF 浓缩物(Voncento)的有效性和安全性:OPALE 多中心观察性研究。
Blood Transfus. 2021 Mar;19(2):152-157. doi: 10.2450/2020.0246-20. Epub 2020 Nov 27.
4
Presurgical pharmacokinetic analysis of a von Willebrand factor/factor VIII (VWF/FVIII) concentrate in patients with von Willebrand's disease (VWD) has limited value in dosing for surgery.在接受手术的血管性血友病(VWD)患者中,对 von Willebrand 因子/因子 VIII(VWF/FVIII)浓缩物进行术前药代动力学分析在剂量设定方面价值有限。
Haemophilia. 2011 Sep;17(5):752-8. doi: 10.1111/j.1365-2516.2011.02583.x. Epub 2011 Jun 20.
5
The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study.两种血管性血友病因子(VWF)/ 凝血因子 VIII(FVIII)浓缩物在先天性血管性血友病患者中的药代动力学多样性。一项前瞻性、随机交叉研究的结果。
Thromb Haemost. 2011 Aug;106(2):279-88. doi: 10.1160/TH11-02-0057. Epub 2011 Jul 4.
6
von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease.人血管性血友病因子/因子 VIII 浓缩物(Humat-P)治疗成人和儿童血管性血友病择期手术。
Haemophilia. 2011 Nov;17(6):895-905. doi: 10.1111/j.1365-2516.2011.02534.x. Epub 2011 Apr 27.
7
Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery.新一代血管性血友病因子/因子 VIII 浓缩物(Wilate®)在血管性血友病患者手术围手术期止血管理中的疗效和安全性。
Thromb Haemost. 2011 Jun;105(6):1072-9. doi: 10.1160/TH10-10-0631. Epub 2011 Mar 24.
8
Safety and efficacy of a von Willebrand factor/factor VIII concentrate (Wilate®): a single centre experience.血管性血友病因子/凝血因子VIII浓缩剂(Wilate®)的安全性和有效性:单中心经验
Haemophilia. 2014 Nov;20(6):846-53. doi: 10.1111/hae.12496. Epub 2014 Aug 7.
9
von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery.基于药代动力学的血管性血友病因子/凝血因子VIII浓缩剂(海莫莱士)给药:择期手术的一项前瞻性多中心试验
J Thromb Haemost. 2007 Jul;5(7):1420-30. doi: 10.1111/j.1538-7836.2007.02588.x. Epub 2007 Apr 16.
10
Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).使用中间纯度的凝血因子VIII-血管性血友病因子浓缩物(海莫莱士)对2型血管性血友病患者进行大手术时的出血预防。
Blood Coagul Fibrinolysis. 2004 Jun;15(4):323-30. doi: 10.1097/00001721-200406000-00006.

引用本文的文献

1
From Circulating Biomarkers to Polymorphic Variants: A Narrative Review of Challenges in Thrombophilia Evaluation.从循环生物标志物到多态性变体:血栓形成倾向评估中挑战的叙述性综述
J Clin Med. 2025 May 15;14(10):3448. doi: 10.3390/jcm14103448.